HKD 11.24
(1.81%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 544.59 Million CNY | 29.8% |
2022 | 419.55 Million CNY | -5.6% |
2021 | 444.44 Million CNY | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 711.94 Million CNY | 0.0% |
2024 Q1 | 711.94 Million CNY | 30.73% |
2023 Q4 | 544.59 Million CNY | 24.82% |
2023 FY | 544.59 Million CNY | 29.8% |
2023 Q3 | 436.3 Million CNY | 0.0% |
2023 Q1 | -661.41 Million CNY | -257.65% |
2022 Q4 | 419.55 Million CNY | 0.0% |
2022 FY | 419.55 Million CNY | -5.6% |
2021 FY | 444.44 Million CNY | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Uni-Bio Science Group Limited | 152.81 Million HKD | -256.367% |
CK Life Sciences Int'l., (Holdings) Inc. | 7.05 Billion HKD | 92.284% |